Not intended for US-, Canada- and UK-based media First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative pote
Collaboration complements Merck’s internal expertise and in-house ADC approach Companies focused on discovering novel STING-agonist ADCs for up to two targets leveraging Mersana’s proprietary Immunosy
Company aims to launch one new product or indication every 1.5 years on average, bolstered by external innovation Phase III assets xevinapant and evobrutinib are expected to drive next wave of launche
Merck Foundation, the philanthropic arm of Merck KGaA Germany marks “World Heart Day 2022” in partnership with African First Ladies, Ministries of Health, Medical Societies, and Academia, through thei
Merck Foundation provided around 100 scholarships to doctors on 32 critical specialties in Zimbabwe. At the same occasions, Merck Foundation Zimbabwe Alumni Summit and Merck Foundation Awards ceremony
/newsonfloor/media/post_banners/WmqR8EFx4HJXidkGgaHo.jpg)
/newsonfloor/media/post_banners/uFUfHLmdQee7GyFpwtsb.jpeg)
/newsonfloor/media/post_banners/Oi2W45qocZGlPrZng1NT.jpg)
/newsonfloor/media/post_banners/Fzsm1fbITBFstl1osqoD.jpg)
/newsonfloor/media/post_banners/93EsVbs8WztgzS1RpxEh.jpg)
/newsonfloor/media/post_banners/isXS4LOoZIIwwO9fvx59.jpg)
